vs
富邦金控（FBK）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是富邦金控的1.2倍（$207.3M vs $178.6M），富邦金控净利率更高（31.9% vs -62.0%，领先93.9%），富邦金控同比增速更快（37.0% vs 25.9%），富邦金控自由现金流更多（$147.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 28.9%）
富邦金融控股股份有限公司是一家金融投资控股企业，旗下核心子公司涵盖富邦投信、富邦产险、富邦证券、富邦银行、富邦人寿、富邦华一银行及富邦银行（香港）等，集团于2001年12月19日正式成立，可为客户提供覆盖全业态的综合金融服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
FBK vs RARE — 直观对比
营收规模更大
RARE
是对方的1.2倍
$178.6M
营收增速更快
FBK
高出11.1%
25.9%
净利率更高
FBK
高出93.9%
-62.0%
自由现金流更多
FBK
多$247.8M
$-100.8M
两年增速更快
RARE
近两年复合增速
28.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $178.6M | $207.3M |
| 净利润 | $57.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 39.1% | -54.7% |
| 净利率 | 31.9% | -62.0% |
| 营收同比 | 37.0% | 25.9% |
| 净利润同比 | 50.4% | 3.5% |
| 每股收益（稀释后） | $1.12 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FBKRARE
| Q4 25 | $178.6M | $207.3M | ||
| Q3 25 | $173.9M | $159.9M | ||
| Q2 25 | $76.9M | $166.5M | ||
| Q1 25 | $130.7M | $139.3M | ||
| Q4 24 | $130.4M | $164.6M | ||
| Q3 24 | $89.5M | $139.5M | ||
| Q2 24 | $128.2M | $147.0M | ||
| Q1 24 | $107.5M | $108.8M |
净利润FBKRARE
| Q4 25 | $57.0M | $-128.6M | ||
| Q3 25 | $23.4M | $-180.4M | ||
| Q2 25 | $2.9M | $-115.0M | ||
| Q1 25 | $39.4M | $-151.1M | ||
| Q4 24 | $37.9M | $-133.2M | ||
| Q3 24 | $10.2M | $-133.5M | ||
| Q2 24 | $40.0M | $-131.6M | ||
| Q1 24 | $27.9M | $-170.7M |
营业利润率FBKRARE
| Q4 25 | 39.1% | -54.7% | ||
| Q3 25 | 17.0% | -106.9% | ||
| Q2 25 | -12.7% | -64.8% | ||
| Q1 25 | 37.4% | -102.6% | ||
| Q4 24 | 38.4% | -74.3% | ||
| Q3 24 | 12.7% | -94.6% | ||
| Q2 24 | 39.7% | -79.1% | ||
| Q1 24 | 31.9% | -151.9% |
净利率FBKRARE
| Q4 25 | 31.9% | -62.0% | ||
| Q3 25 | 13.4% | -112.8% | ||
| Q2 25 | 3.8% | -69.0% | ||
| Q1 25 | 30.1% | -108.5% | ||
| Q4 24 | 29.1% | -80.9% | ||
| Q3 24 | 11.4% | -95.7% | ||
| Q2 24 | 31.2% | -89.5% | ||
| Q1 24 | 26.0% | -156.8% |
每股收益（稀释后）FBKRARE
| Q4 25 | $1.12 | $-1.28 | ||
| Q3 25 | $0.43 | $-1.81 | ||
| Q2 25 | $0.06 | $-1.17 | ||
| Q1 25 | $0.84 | $-1.57 | ||
| Q4 24 | $0.82 | $-1.34 | ||
| Q3 24 | $0.22 | $-1.40 | ||
| Q2 24 | $0.85 | $-1.52 | ||
| Q1 24 | $0.59 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $421.0M |
| 总债务越低越好 | $212.8M | — |
| 股东权益账面价值 | $1.9B | $-80.0M |
| 总资产 | $16.3B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.11× | — |
8季度趋势，按日历期对齐
现金及短期投资FBKRARE
| Q4 25 | $1.2B | $421.0M | ||
| Q3 25 | $1.3B | $202.5M | ||
| Q2 25 | $1.2B | $176.3M | ||
| Q1 25 | $794.7M | $127.1M | ||
| Q4 24 | $1.0B | $174.0M | ||
| Q3 24 | $951.8M | $150.6M | ||
| Q2 24 | $800.9M | $480.7M | ||
| Q1 24 | $870.7M | $112.3M |
总债务FBKRARE
| Q4 25 | $212.8M | — | ||
| Q3 25 | $213.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $176.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FBKRARE
| Q4 25 | $1.9B | $-80.0M | ||
| Q3 25 | $2.0B | $9.2M | ||
| Q2 25 | $1.6B | $151.3M | ||
| Q1 25 | $1.6B | $144.2M | ||
| Q4 24 | $1.6B | $255.0M | ||
| Q3 24 | $1.6B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
总资产FBKRARE
| Q4 25 | $16.3B | $1.5B | ||
| Q3 25 | $16.2B | $1.2B | ||
| Q2 25 | $13.4B | $1.3B | ||
| Q1 25 | $13.1B | $1.3B | ||
| Q4 24 | $13.2B | $1.5B | ||
| Q3 24 | $12.9B | $1.5B | ||
| Q2 24 | $12.5B | $1.6B | ||
| Q1 24 | $12.5B | $1.3B |
负债/权益比FBKRARE
| Q4 25 | 0.11× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.11× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $155.9M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $147.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 82.3% | -48.6% |
| 资本支出强度资本支出/营收 | 5.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.74× | — |
| 过去12个月自由现金流最近4个季度 | $242.8M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流FBKRARE
| Q4 25 | $155.9M | $-99.8M | ||
| Q3 25 | $47.7M | $-91.4M | ||
| Q2 25 | $71.8M | $-108.3M | ||
| Q1 25 | $-16.5M | $-166.5M | ||
| Q4 24 | $138.8M | $-79.3M | ||
| Q3 24 | $57.8M | $-67.0M | ||
| Q2 24 | $30.6M | $-77.0M | ||
| Q1 24 | $36.3M | $-190.7M |
自由现金流FBKRARE
| Q4 25 | $147.0M | $-100.8M | ||
| Q3 25 | $45.6M | $-92.7M | ||
| Q2 25 | $68.4M | $-110.7M | ||
| Q1 25 | $-18.1M | $-167.8M | ||
| Q4 24 | $132.3M | $-79.5M | ||
| Q3 24 | $56.7M | $-68.6M | ||
| Q2 24 | $28.4M | $-79.0M | ||
| Q1 24 | $34.6M | $-193.9M |
自由现金流率FBKRARE
| Q4 25 | 82.3% | -48.6% | ||
| Q3 25 | 26.2% | -58.0% | ||
| Q2 25 | 89.0% | -66.5% | ||
| Q1 25 | -13.9% | -120.5% | ||
| Q4 24 | 101.4% | -48.3% | ||
| Q3 24 | 63.3% | -49.2% | ||
| Q2 24 | 22.1% | -53.7% | ||
| Q1 24 | 32.2% | -178.2% |
资本支出强度FBKRARE
| Q4 25 | 5.0% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 4.4% | 1.5% | ||
| Q1 25 | 1.3% | 1.0% | ||
| Q4 24 | 5.0% | 0.1% | ||
| Q3 24 | 1.2% | 1.2% | ||
| Q2 24 | 1.7% | 1.4% | ||
| Q1 24 | 1.5% | 3.0% |
现金转化率FBKRARE
| Q4 25 | 2.74× | — | ||
| Q3 25 | 2.04× | — | ||
| Q2 25 | 24.68× | — | ||
| Q1 25 | -0.42× | — | ||
| Q4 24 | 3.66× | — | ||
| Q3 24 | 5.65× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.30× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FBK
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
